Shares of Metsera, Inc. (NASDAQ:MTSR – Get Free Report) hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $24.70 and last traded at $25.14, with a volume of 233191 shares. The stock had previously closed at $27.21.
Analysts Set New Price Targets
Several equities analysts have issued reports on MTSR shares. Guggenheim started coverage on Metsera in a report on Tuesday. They set a “buy” rating and a $56.00 price objective on the stock. Bank of America started coverage on Metsera in a report on Tuesday. They set a “buy” rating and a $38.00 price objective on the stock. Cantor Fitzgerald started coverage on Metsera in a report on Tuesday. They set an “overweight” rating on the stock. Finally, Evercore ISI began coverage on Metsera in a report on Tuesday. They set an “outperform” rating on the stock.
Check Out Our Latest Research Report on MTSR
Metsera Price Performance
Metsera Company Profile
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Recommended Stories
- Five stocks we like better than Metsera
- Consumer Discretionary Stocks Explained
- Autodesk Designs Value for Investors: Uptrend Set to Continue
- 3 Stocks to Consider Buying in October
- Anheuser-Busch Stock Rallies—Is the King of Beers Back?
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- MarketBeat Week in Review – 02/24 – 02/28
Receive News & Ratings for Metsera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metsera and related companies with MarketBeat.com's FREE daily email newsletter.
